Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
1.
Microb Pathog ; 112: 1-4, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-28923601

RESUMO

Studies show that highly diluted medications demonstrate benefits in treating infections, constituting an alternative for their treatment. The present study evaluated the effects of Lycopodium clavatum, dynamization 13c, in Wistar rats infected with T. cruzi. In this study 42 male rats were intraperitoneally inoculated with T. cruzi - Y strain and allocated into groups: IC (infected control group) and Ly (treated with L. clavatum 13c). The cytokines dosage (IFN-γ, IL-12, IL-10, IL-4), quantification and morphometry of myenteric neurons were evaluated. The treatment with L. clavatum modifies the immune response, with increase of IFN-γ on day 10 a.i. and IL-12 on day 24 a.i., decrease of IL-10 concentration on day 10 a.i. and subsequent increase of this cytokine and IL-4 on day 24 a.i., affording a bigger number of myenteric neurons compared to IC group. Thus, L. clavatum 13c promoted on rats infected with T. cruzi a beneficial immunomodulatory action reducing the pathogenic progression of digestive Chagas disease.


Assuntos
Doença de Chagas/imunologia , Imunomodulação , Lycopodium/química , Neurônios/imunologia , Extratos Vegetais/farmacologia , Trypanosoma cruzi/efeitos dos fármacos , Animais , Corpo Celular/efeitos dos fármacos , Corpo Celular/imunologia , Corpo Celular/parasitologia , Corpo Celular/patologia , Doença de Chagas/tratamento farmacológico , Colo/inervação , Colo/parasitologia , Colo/patologia , Citocinas/metabolismo , Digestão , Modelos Animais de Doenças , Homeopatia , Interferon gama/metabolismo , Interleucina-10/metabolismo , Interleucina-12/metabolismo , Interleucina-4/metabolismo , Masculino , Neurônios/efeitos dos fármacos , Neurônios/parasitologia , Neurônios/patologia , Ratos , Ratos Wistar , Trypanosoma cruzi/imunologia , Trypanosoma cruzi/patogenicidade
2.
BMC Complement Altern Med ; 14: 104, 2014 Mar 19.
Artigo em Inglês | MEDLINE | ID: mdl-24642002

RESUMO

BACKGROUND: Gelsemium sempervirens L. (Gelsemium s.) is a traditional medicinal plant, employed as an anxiolytic at ultra-low doses and animal models recently confirmed this activity. However the mechanisms by which it might operate on the nervous system are largely unknown. This work investigates the gene expression of a human neurocyte cell line treated with increasing dilutions of Gelsemium s. extract. METHODS: Starting from the crude extract, six 100 × (centesimal, c) dilutions of Gelsemium s. (2c, 3c, 4c, 5c, 9c and 30c) were prepared according to the French homeopathic pharmacopoeia. Human SH-SY5Y neuroblastoma cells were exposed for 24 h to test dilutions, and their transcriptome compared by microarray to that of cells treated with control vehicle solutions. RESULTS: Exposure to the Gelsemium s. 2c dilution (the highest dose employed, corresponding to a gelsemine concentration of 6.5 × 10(-9) M) significantly changed the expression of 56 genes, of which 49 were down-regulated and 7 were overexpressed. Several of the down-regulated genes belonged to G-protein coupled receptor signaling pathways, calcium homeostasis, inflammatory response and neuropeptide receptors. Fisher exact test, applied to the group of 49 genes down-regulated by Gelsemium s. 2c, showed that the direction of effects was significantly maintained across the treatment with high homeopathic dilutions, even though the size of the differences was distributed in a small range. CONCLUSIONS: The study shows that Gelsemium s., a medicinal plant used in traditional remedies and homeopathy, modulates a series of genes involved in neuronal function. A small, but statistically significant, response was detected even to very low doses/high dilutions (up to 30c), indicating that the human neurocyte genome is extremely sensitive to this regulation.


Assuntos
Ansiolíticos/farmacologia , Gelsemium/química , Expressão Gênica/efeitos dos fármacos , Homeopatia , Materia Medica/farmacologia , Neurônios/efeitos dos fármacos , Extratos Vegetais/farmacologia , Alcaloides/administração & dosagem , Alcaloides/farmacologia , Ansiolíticos/administração & dosagem , Humanos , Materia Medica/administração & dosagem , Neurônios/metabolismo , Extratos Vegetais/administração & dosagem , Receptores de Neuropeptídeos/genética , Transdução de Sinais/genética
3.
Anesthesiology ; 110(6): 1261-70, 2009 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19417602

RESUMO

BACKGROUND: Many studies have indicated that acceleromyography and mechanomyography cannot be used interchangeably. To improve the agreement between the two methods, it has been suggested to use a preload and to refer all train-of-four (TOF) ratios to the control TOF (normalization) when using acceleromyography. The first purpose of this study was to test whether a preload applied to acceleromyography would increase the precision and the agreement with mechanomyography. The second purpose was to evaluate whether normalization would improve the agreement with mechanomyography. METHODS: Sixty patients were randomized to acceleromyography with or without a preload (Hand Adapter; Organon, Oss, the Netherlands). On the contralateral arm, mechanomyography was used. Anesthesia was induced with propofol and an opioid, and neuromuscular block with 0.6 mg/kg rocuronium. The precision and the bias and limits of agreement (with or without normalization) between the methods were evaluated using TOF stimulation. RESULTS: Preload improved the precision of acceleromyography by 21%, but it also increased the mean control TOF ratio from 1.07 to 1.13. Normalization of the acceleromyographic TOF ratios diminished the bias to mechanomyography during recovery (e.g., from 0.15 to 0.05 at TOF 0.90); when the mechanomyographic TOF values were normalized as well, the bias was eliminated. However, normalization did not exclude wide individual differences between acceleromyography and mechanomyography (+/- 0.10-0.20 at TOF 0.90). CONCLUSION: Preload increases the precision of acceleromyography, and normalization of the TOF ratios decreases bias in relation to mechanomyography. When both acceleromyography and mechanomyography are normalized, there is no significant bias between the two methods.


Assuntos
Monitorização Intraoperatória/métodos , Miografia/métodos , Aceleração , Adulto , Anestesia Geral , Estimulação Elétrica , Feminino , Mãos/fisiologia , Humanos , Masculino , Pessoa de Meia-Idade , Músculo Esquelético/efeitos dos fármacos , Músculo Esquelético/fisiologia , Neurônios/efeitos dos fármacos , Neurônios/fisiologia , Estimulação Física , Valores de Referência , Reprodutibilidade dos Testes , Nervo Ulnar/fisiologia
4.
Br J Pharmacol ; 64(4): 589-99, 1978 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-728686

RESUMO

1. The effects of pancuronium bromide on the cardiovascular system of the pithed rat were examined. Pancuronium had two effects, a short-lasting cardiovascular stimulation following injection and a longer-lasting potentiation of responses to sympathetic nerve stimulation. 2 The initial effect of pancuronium was compared with that of tyramine. The cardioaccelerator but not the pressor responses to both pancuronium and tyramine were significantly reduced following sympathectomy with 6-hydroxydopamine (6-OHDA). 3 The action of pancuronium in potentiating sympathetic nerve responses was compared with that of known blockers of the neuronal uptake of noradrenaline (NA). Pancuronium (1 mg/kg) and cocaine (0.5 mg/kg) potentiated cardioaccelerator and pressor responses to sympathetic stimulation. These effects of pancuronium could be obtained following adrenalectomy and during neuromuscular blockade with gallamine. Pancuronium and uptake blockers potentiated the cardioaccelerator response to NA, reduced the response to tyramine, but did not affect the response to isoprenaline. Pancuronium and uptake blockers potentiated the pressor response to NA, but did not affect the response to tyramine or clonidine. 4 Following sympathectomy with 6-OHDA, pancuronium failed to potentiate cardioaccelerator and pressor responses to NA. 5 These results are discussed in relation to two main cardiovascular effects of pancuronium; an indirect sympathomimetic action and blockade of the neuronal uptake of NA.


Assuntos
Hemodinâmica/efeitos dos fármacos , Neurônios/metabolismo , Norepinefrina/metabolismo , Pancurônio/farmacologia , Simpatomiméticos , Adrenalectomia , Animais , Pressão Sanguínea/efeitos dos fármacos , Frequência Cardíaca/efeitos dos fármacos , Masculino , Neurônios/efeitos dos fármacos , Ratos , Medula Espinal/fisiologia , Simpatectomia
5.
Neuroreport ; 12(2): 335-9, 2001 Feb 12.
Artigo em Inglês | MEDLINE | ID: mdl-11209946

RESUMO

The protective effects of ultra-low doses (ULD) of glutamate against glutamate toxicity was studied in primary rat spinal, cortical and cerebellar neurons. Neurons were exposed to four subtoxic, ultra-low concentrations of glutamate (10(-18) M, 10(-20)M, 10(-22) M and 10(-30) M) for 72 h and then subsequently challenged with toxic concentrations (25 microM) of glutamate. Neuron viability was consistently 10% higher in spinal and cortical neurons pre-exposed to glutamate concentrations of 10(-18) M and 10(-22) M, and in cerebellar neurons pre-exposed to 10(-20) M and 10(-30) M. Using laser scanning confocal microscopy and the fluorescent calcium probe fluo-3, we found no alterations in intracellular calcium dynamics in the protected cells. This protective effect is consistent with a growing body of evidence for tolerance induced by low-dose toxin exposure but is the first time that such tolerance has been demonstrated with ultra-low glutamate exposure. Our data show that pre-exposure of neuronal cells to ULD glutamate can protect against subsequent exposure to toxic levels of glutamate.


Assuntos
Ácido Glutâmico/toxicidade , Homeopatia , Neurônios/efeitos dos fármacos , Fármacos Neuroprotetores/farmacologia , Animais , Transporte Biológico/efeitos dos fármacos , Cálcio/metabolismo , Membrana Celular/metabolismo , Células Cultivadas , Relação Dose-Resposta a Droga , Técnicas de Diluição do Indicador , Neurônios/citologia , Neurônios/metabolismo , Ratos , Ratos Sprague-Dawley
6.
J Ethnopharmacol ; 153(2): 535-9, 2014 Apr 28.
Artigo em Inglês | MEDLINE | ID: mdl-24613275

RESUMO

ETHNOPHARMACOLOGICAL RELEVANCE: Gelsemium sempervirens L. is a traditional medicinal plant mainly distributed in the southeastern of the United States, employed in phytotheraphy and homeopathy as nervous system relaxant to treat various types of anxiety, pain, headache and other ailments. Although animal models showed its effectiveness, the mechanisms by which it might operate on the nervous system are largely unknown. This study investigated for the first time by a real-time PCR technique (RT-PCR Array) the gene expression of a panel of human neurotransmitter receptors and regulators, involved in neuronal excitatory signaling, on a neurocyte cell line. MATERIALS AND METHODS: Human SH-SY5Y neuroblastoma cells were exposed for 24h to Gelsemium sempervirens at 2c and 9c dilutions (i.e. 2 and 9-fold centesimal dilutions from mother tincture) and the gene expression profile compared to that of cells treated with control vehicle solutions. RESULTS: Exposure to the Gelsemium sempervirens 2c dilution, containing a nanomolar concentration of active principle gelsemine, induced a down-regulation of most genes of this array. In particular, the treated cells showed a statistically significant decrease of the prokineticin receptor 2, whose ligand is a neuropeptide involved in nociception, anxiety and depression-like behavior. CONCLUSIONS: Overall, the results indicate a negative modulation trend in neuronal excitatory signaling, which can suggest new working hypotheses on the anxiolytic and analgesic action of this plant.


Assuntos
Gelsemium , Perfilação da Expressão Gênica/métodos , Neurônios/efeitos dos fármacos , Extratos Vegetais/farmacologia , Transdução de Sinais/efeitos dos fármacos , Linhagem Celular Tumoral , Humanos , Neurônios/fisiologia , Extratos Vegetais/isolamento & purificação , Transdução de Sinais/fisiologia , Resultado do Tratamento
9.
Arch Psychiatr Nervenkr (1970) ; 221(3): 183-97, 1976 Apr 30.
Artigo em Inglês | MEDLINE | ID: mdl-962573

RESUMO

Considerable progress in opiate research has been made during the last few years regarding the identification and localization of opiate receptors in vitro and in vivo, the analysis of drug-receptor interactions and the characterization of an endogenous ligand of the opiate receptor. There is little evidence that effects induced by chronic exposure to opiates - development of tolerance and dependence -are due to changes in opiate receptor mechanisms; it is supposed that the adaptive changes occur mainly in the chain of events triggered by the drug-receptor interaction. Such changes may be directly or indirectly related to the metabolism of neurotransmitters and/or cyclic nucleotides. The obvious links between physical and psychic equivalents of opiate dependence are discussed. Present data points to the significance of brain stem and limbic structures in both these processes, monoamines probably playing an important role. Relations between psychic manifestations of opiate addiction and mental disorders are pointed out.


Assuntos
Encéfalo/metabolismo , Transtornos Mentais/metabolismo , Ópio/farmacologia , Receptores de Droga/efeitos dos fármacos , Transtornos Relacionados ao Uso de Substâncias/metabolismo , Animais , Catecolaminas/fisiologia , Sinergismo Farmacológico , Humanos , Camundongos , Morfina/farmacologia , Neurônios/efeitos dos fármacos , Ópio/análogos & derivados , Ópio/antagonistas & inibidores , Ratos
10.
Br J Anaesth ; 52(3): 313-7, 1980 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-7370147

RESUMO

The cardiovascular effects of pancuronium may be caused partly by an interaction of this drug with the sympathetic nervous system. We examined one possible mechanism of interaction, the effect on the re-uptake processes for noradrenaline. Pancuronium and its closely related steroidal homologues, Org. 6368, Org. 7268 and NC 45, were studied at a high concentration (500 mumol litre-1) for inhibition of the uptake of tritiated noradrenaline into neuronal sites (Uptake1) and extraneuronal sites (Uptake2) in the isolated perfused rat heart. All drugs tested caused almost total inhibition of Uptake1. The bis-quaternary steroids pancuronium and Org. 6368 were selective for Uptake1 inhibition, the mono-quaternary steriods Org. 7268 and NC45 also produced significant inhibition of Uptake2. Uptake1 inhibition was investigated in detail using lesser concentrations of the compounds. All four steroids were found to cause a concentration-dependent inhibition of Uptake1. It seems likely, therefore, that inhibition of neuronal uptake of noradrenaline plays a significant role in the aetiology of the chronotropic actions of pancuronium in the rat.


Assuntos
Miocárdio/metabolismo , Neurônios/metabolismo , Norepinefrina/metabolismo , Pancurônio/análogos & derivados , Pancurônio/farmacologia , Animais , Depressão Química , Coração/efeitos dos fármacos , Técnicas In Vitro , Masculino , Neurônios/efeitos dos fármacos , Ratos , Sistema Nervoso Simpático/efeitos dos fármacos , Sistema Nervoso Simpático/metabolismo
11.
Arzneimittelforschung ; 30(2a): 346-57, 1980.
Artigo em Inglês | MEDLINE | ID: mdl-6155921

RESUMO

2 beta, 16 beta-Bis-(4'-dimethyl-1'-piperazino)-3 alpha, 17 beta-diacetoxy-5 alpha-androstane dibromide (pipecurium bromide, RGH-1106, Arduan), a newly synthetized bisquaternary steroid, produces competitive neuromuscular blockade in chicks, rats, cats, rabbits and dogs. The onset of paralysis is rapid. Pipecurium bromide is 2-4 times as potent as pancuronium bromide. The duration of action is about twice as long as that of pancuronium bromide in equiactive doses. Neostigmine rapidly and completely antagonises the neuromuscular blockade caused by pipecurium bromide. Even one hundred times higher dose than the effective blocking dose (2-6 microgram/kg) does not influence the cardiovascular system. Higher doses (1-2 mg/kg) cause transient decrease in blood pressure, in 10-20 mg/kg doses pipecurium bromide has ganglion blocking effect. In 1 mg/kg dose pipecurium bromide does not release histamine. Many times higher doses than the effective dose administered for 20 days, do not cause any toxic damage to respirated beagle dogs. According to examinations in rats, the placentary transfer of pipecurium bromide is lower than 0.1%. According to preliminary clinical examinations pipecurium bromide is free from side effects, and elicits as well controllable muscle relaxation.


Assuntos
Androstano-3,17-diol/farmacologia , Androstanóis/farmacologia , Bloqueadores Neuromusculares/farmacologia , Piperazinas/farmacologia , Potenciais de Ação/efeitos dos fármacos , Androstano-3,17-diol/análogos & derivados , Androstano-3,17-diol/toxicidade , Anestesia , Animais , Gatos , Cães , Interações Medicamentosas , Feminino , Hemodinâmica/efeitos dos fármacos , Liberação de Histamina/efeitos dos fármacos , Técnicas In Vitro , Masculino , Contração Muscular/efeitos dos fármacos , Bloqueadores Neuromusculares/toxicidade , Neurônios/efeitos dos fármacos , Pancurônio/farmacologia , Pipecurônio , Piperazinas/toxicidade , Coelhos , Ratos , Transmissão Sináptica/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA